Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

MDMA-assisted Therapy in People With Anxiety Related to Advanced Stage Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2010 by Brigham and Women's Hospital.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Mclean Hospital
Information provided by:
Brigham and Women's Hospital
ClinicalTrials.gov Identifier:
NCT00252174
First received: November 9, 2005
Last updated: July 22, 2010
Last verified: July 2010
  Purpose

This is a pilot study intended to find out if 3,4-methylenedioxymethamphetamine (MDMA) is safe and can help people with advanced stage cancer and anxiety arising from the cancer diagnosis.


Condition Intervention Phase
Anxiety Disorder
Cancer
Drug: 3,4-methylenedioxymethamphetamine (MDMA)
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Factorial Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Phase II Dose-response Pilot Study of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy in Subjects With Anxiety Associated With Advanced-stage Cancer.

Resource links provided by NLM:


Further study details as provided by Brigham and Women's Hospital:

Primary Outcome Measures:
  • Anxiety - Spielberger State-Trait Anxiety Inventory (STAI) [ Time Frame: Obtained over the 3 months of active participation ] [ Designated as safety issue: No ]
  • Quality of life - European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) [ Time Frame: Obtained over the 3 months of active participation ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Anxiety - Hamilton Anxiety Rating Scale (HAM-A) [ Time Frame: Obtained over the 3 months of active participation ] [ Designated as safety issue: No ]
  • Quality of life - Functional assessment of chronic illness therapy- spiritual well-being scale (FACIT-Sp),Karnofsky Performance Rating Scale (KPRS), Memorial Symptom Assessment Scale (MSAS), Mini-Mental Status Exam (MMSE), Self-Expansiveness Level For [ Time Frame: Obtained over the 3 months of active participation ] [ Designated as safety issue: No ]
  • Depression - via Hamilton Depression Rating Scale (HAM-D, Beck Hopelessness Scale (BHS) [ Time Frame: Obtained over the 3 months of active participation ] [ Designated as safety issue: No ]
  • Depression, thoughts of death - Schedule of Attitudes Toward Hastened Death (SAHD) [ Time Frame: Obtained over the 3 months of active participation ] [ Designated as safety issue: No ]
  • Daily use of anxiolytics - Daily Diary [ Time Frame: Obtained over the 3 months of active participation ] [ Designated as safety issue: No ]
  • Daily experience of pain - visual analog pain scale (VAPS) [ Time Frame: Obtained over the 3 months of active participation ] [ Designated as safety issue: No ]
  • The Hospital Anxiety and Depression Scale (HADS) [ Time Frame: Obtained over the 3 months of active participation ] [ Designated as safety issue: No ]
  • Daily assessment of anxiety - the Visual Analog Anxiety Scale (VAAS) [ Time Frame: Obtained over the 3 months of active participation ] [ Designated as safety issue: No ]

Estimated Enrollment: 12
Study Start Date: February 2007
Estimated Study Completion Date: March 2011
Estimated Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Stage 1, Active
8 subjects will receive full or nearly full doses of MDMA in Stage 1 and do not continue to participate into Stage 2.
Drug: 3,4-methylenedioxymethamphetamine (MDMA)

Dosage form: capsule

Dosage frequency and duration for the treatment arm (8 subjects in Stage 1 and the other 4 subjects in Stage 1 who may continue into Stage 2):

Session 1: 83.3mg followed 2.5 hours later with optional 41.7 mg for total of 125mg Session 2 (two to three weeks later): 125mg followed 2.5 hours later with optional 62.5mg for total of 187.5 mg.

Active Comparator: Stage 1, Control
4 individuals will receive sub-threshold to threshold minimal doses of MDMA in Stage I
Drug: 3,4-methylenedioxymethamphetamine (MDMA)

Drug:

Dosage form: capsule

Dosage frequency and duration for the control arm (4 subjects):

Session 1: 25 mg followed 2.5 hours later with optional 12.5 mg for total of 37.5 g Session 2 (two to three weeks later): 25 mg followed 2.5 hours later with optional 12.5mg for total of 37.5mg.

Experimental: Stage 2, Active
The 4 subjects assigned in Stage I to the control arm will have the option to continue into Stage 2 to repeat the experimental procedures of Stage I but with open-label MDMA at the near-full to full dosage strength.
Drug: 3,4-methylenedioxymethamphetamine (MDMA)

Dosage form: capsule

Dosage frequency and duration for the treatment arm (8 subjects in Stage 1 and the other 4 subjects in Stage 1 who may continue into Stage 2):

Session 1: 83.3mg followed 2.5 hours later with optional 41.7 mg for total of 125mg Session 2 (two to three weeks later): 125mg followed 2.5 hours later with optional 62.5mg for total of 187.5 mg.


  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis with advanced-stage cancer (usually meaning inoperable or incurable) with a life expectancy of less than 12 months.
  • Anxiety as a result of cancer diagnosis
  • Failure to respond adequately or at all to medication intended to reduce anxiety, or have refused to take anxiolytic medication.
  • Completed or independently decided to end all direct cancer treatments, such as chemotherapy and radiation, two weeks prior to the first experimental (MDMA) session. If subjects wish to initiate or resume treatment for cancer at any point prior to the second experimental (MDMA) session, then they will be withdrawn from the study and will be asked to see the co-investigator oncologist for a final physical examination. Participants will not be withdrawn from the study if they initiate or resume treatment after the second experimental (MDMA) session. Those who are receiving cycles of cancer treatments for only palliative purposes (no longer for any curative reasons or to induce complete remission), may also be included in this study provided that they, as well, have completed their last cycle of treatment at least two weeks prior to the first experimental (MDMA) session and provided that they will not resume another cycle of treatment until after completion of the second experimental (MDMA) session. If a subject receiving palliative cancer treatment decides to receive a next cycle of this cancer treatment prior to the second experimental session, then, again, they will be withdrawn from the study. Participants will not be withdrawn from the study if they initiate or resume palliative cancer treatments after the second experimental (MDMA) session.
  • Willing to commit to and follow all directions and restrictions relating to the study period
  • Must be willing and able to discontinue use of psychiatric medication except that being used to treat anxiety. If still taking medication when enrolled to the study, medication will be discontinued long enough before the first MDMA-assisted psychotherapy session to avoid a drug-drug interaction
  • Must be willing and able to stay overnight at the facility after each MDMA-assisted session.
  • If seeing another psychotherapist, participants must be willing to give the principal investigator permission to communicate with him or her.
  • Female participants of childbearing potential must have a negative pregnancy test and must agree to use an effective form of birth control.

Exclusion Criteria:

  • People with a life expectancy of longer than 12 months
  • Women who are pregnant or nursing, or of child bearing potential and are not practicing an effective means of birth control.
  • People with any dissociative disorder, anorexia nervosa, bulimia nervosa, a primary psychotic disorder or affective disorder other than anxiety related to advanced stage cancer
  • People diagnosed with abuse of or dependence on any substance (other than caffeine or nicotine) in the past 60 days.
  • People with known primary or metastatic cancer of the CNS
  • People with significant, unstable hematological, endocrine, cerebrovascular, cardiovascular, coronary, pulmonary, renal, gastrointestinal, immunocompromising, or neurological disease, including seizure disorder, that in the clinical judgment of the investigators poses too great a potential for side-effects.
  • People with significant peripheral vascular disease, hepatic disease, renal insufficiency, or preexisting or past evidence of hyponatremia.
  • People diagnosed with hypertension, even if well-controlled with medication. A systolic blood pressure of 140 or greater and/or a diastolic blood pressure of 90 or greater will exclude the potential participant from this study.
  • People with liver enzyme values indicative of severely compromised hepatic (liver) function
  • People who weigh less than 45 kg (98 lb)
  • People reporting a history of use of "ecstasy" (illicit drug preparations purported to contain MDMA) at any time within the previous 3 months.
  • People reasonably judged to present a serious suicide risk or who are likely to require psychiatric hospitalization during the course of the study
  • People requiring psychotropic medication other than anxiolytic medication or for pain control
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00252174

Contacts
Contact: John H. Halpern, M.D. 617-855-2911 john_halpern@hms.harvard.edu

Locations
United States, Massachusetts
McLean Hospital Recruiting
Belmont, Massachusetts, United States, 02478-9106
Contact: John H Halpern, MD    617-855-3703    john_halpern@hms.harvard.edu   
Principal Investigator: John H Halpern, MD         
Sponsors and Collaborators
Brigham and Women's Hospital
Mclean Hospital
Investigators
Principal Investigator: John H Halpern, MD Mclean Hospital
  More Information

Additional Information:
No publications provided

Responsible Party: John H. Halpern, M.D., Director of The Laboratory for Integrative Psychiatry, Division of Alcohol and Drug Abuse, McLean Hospital
ClinicalTrials.gov Identifier: NCT00252174     History of Changes
Other Study ID Numbers: 76,770
Study First Received: November 9, 2005
Last Updated: July 22, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by Brigham and Women's Hospital:
MDMA
cancer
anxiety
psychotherapy
quality of life

Additional relevant MeSH terms:
Anxiety Disorders
Mental Disorders
N-Methyl-3,4-methylenedioxyamphetamine
Adrenergic Agents
Adrenergic Uptake Inhibitors
Central Nervous System Agents
Hallucinogens
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on November 25, 2014